title: Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study.
abstract: Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
authors: Headaches and Cerebrovascular Disorders Unit, C. Besta National Neurological Institute, Via Celoria 11, I-20133, Milan, Italy. bussone@istituto-besta.it
authors: G
authors: G
authors: Bussone
authors: S
authors: S
authors: Usai
authors: D
authors: D
authors: D'Amico